Focus: Sequence Bio is a genomic analysis biotechnology company focused on identifying drug targets for oncology. The company operates as a pre-revenue biotech with a highly specialized, research-driven model.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Sequence Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Sequence Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sequence Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Efficient Gene Expression System in Medaka Embryos Enables Functional Characterization of nt5c1a Paralogs Involved in Inosine Monophosphate Metabolism.
Haplotype-resolved genome of Schizothorax nukiangensis sheds light on polyploidy and altitudinal adaptation in freshwater fishes.
Generative models for antimicrobial peptide design: auto-encoders and beyond.
Meloidogyne vitis infecting mulberry (Morus alba L.) in Yunnan, China: morphology, molecular identification, and pathogenicity.
Haplotype-resolved genome assembly of a cultivated variety of Zizania latifolia (Zhejiao7).
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo